Neutralizing IL-6 in the CT26 colon cancer model restored microbial balance and eubiosis, while elevated serum LBP and IL-6 emerged as robust biomarkers that can stratify prognosis and guide diagnosis and therapy for CC [85,86]. Here, IL6 is linked to malignant colon neoplasm.